Controversial drug at center of multibillion-dollar Amgen deal faces more questions after paper retracted

The FDA in January sent the acquirer a request to withdraw the $19,000-a-month drug at the heart of the deal from the market.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks